1. Home
  2. IKT vs RDCM Comparison

IKT vs RDCM Comparison

Compare IKT & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.07

Market Cap

201.3M

Sector

Health Care

ML Signal

HOLD

Logo Radcom Ltd.

RDCM

Radcom Ltd.

HOLD

Current Price

$11.65

Market Cap

205.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IKT
RDCM
Founded
2008
1985
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
201.3M
205.7M
IPO Year
2020
1999

Fundamental Metrics

Financial Performance
Metric
IKT
RDCM
Price
$2.07
$11.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$6.00
$18.00
AVG Volume (30 Days)
1.8M
91.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
67.51
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$11.50
Revenue Next Year
N/A
$9.74
P/E Ratio
N/A
$16.35
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$9.88
52 Week High
$2.58
$15.14

Technical Indicators

Market Signals
Indicator
IKT
RDCM
Relative Strength Index (RSI) 67.70 42.85
Support Level $1.45 $10.64
Resistance Level $2.11 $13.65
Average True Range (ATR) 0.14 0.73
MACD 0.05 -0.03
Stochastic Oscillator 75.36 34.60

Price Performance

Historical Comparison
IKT
RDCM

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About RDCM Radcom Ltd.

Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.

Share on Social Networks: